Put companies on watchlist
SynBiotic SE
ISIN: DE000A3E5A59
WKN: A3E5A5
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SynBiotic SE · ISIN: DE000A3E5A59 · EQS - Company News (19 News)
Country: Germany · Primary market: Germany · EQS NID: 1253421
01 December 2021 02:54PM

SynBiotic SE: Most important cannabis merger in Europe


DGAP-News: SynBiotic SE / Key word(s): Takeover
SynBiotic SE: Most important cannabis merger in Europe

01.12.2021 / 14:54
The issuer is solely responsible for the content of this announcement.



SynBiotic SE: Most important cannabis merger in Europe

- SynBiotic SE acquires 50.1% of Daniel Kruse's group of companies at a valuation of EUR 11.2 million

- Hanf Farm GmbH, Hempro International GmbH, Hemp Factory GmbH and MH medical hemp GmbH join the German cannabis group

- EIHA President Daniel Kruse and industry pioneer Rafael Dulon bring a combined half a century of cannabis expertise to SynBiotic SE

- SynBiotic SE raises sales forecast for 2021 to EUR 15 million (pro forma consolidated)

Munich, November 30, 2021.
It is the most significant merger in the European cannabis sector. SynBiotic SE has acquired 50.1% of Daniel Kruse's group of companies, with four leading companies in their fields, at a valuation of EUR 11.2 million, thereby securing the subsequent acquisition of the remaining 49.9% by option. The listed cannabis group is hence raising its sales forecast for 2021 to EUR 15 million.

With Daniel Kruse's four companies, Hanf Farm GmbH, Hempro International GmbH, Hemp Factory GmbH and MH medical hemp GmbH, SynBiotic SE's portfolio is being enriched by important infrastructures and profitable brands. Lars Müller, CEO of SynBiotic SE: "The cooperation with Daniel Kruse is a genuine accolade in the cannabis sector. SynBiotic SE will benefit massively from what amounts to over half a century of combined know-how gathered by industry pioneers Daniel Kruse and Rafael Dulon. So far, the only comparable acquisitions have taken place in Canada. This makes this merger the most significant in the European cannabis sector. I am greatly honored by the trust Daniel Kruse and Rafael Dulon have displayed in SynBiotic SE; this shows that we are on the right track with our vision."

Daniel Kruse has been an entrepreneur in the hemp food industry for over 25 years, with a focus on cannabinoids such as CBD. He is also President of the European Industrial Hemp Association (EIHA). His cooperation with international experts as well as with the advisory committee of the EIHA combines his well-founded know-how from practice and science in the hemp and food industry. Kruse advocates on behalf of hemp industry stakeholders before the European Union and the German government. With his work, he has made a significant contribution to advancing the legal and regulatory framework for the hemp industry.

Daniel Kruse, industry pioneer, entrepreneur and President of the European Industrial Hemp Association (EIHA), commented on the merger: "After 25 years in the hemp industry, it is a great pleasure and honor for me to have found the right partner for the coming decades with SynBiotic SE. Our decades of experience alongside the supply chain of our group of companies find an excellent complement in the enormous dynamics of SynBiotic SE. The appealing nature and charisma of Lars Müller and his team contribute, but it is above all their displaying the highest professionalism and efficiency that has won us over. This combination makes SynBiotic SE the next Unicorn candidate and an ideal partner for me. The European hemp and cannabis market is set to become one of the most exciting and successful industries in the coming years. The challenges yet to be mastered are well known, but the resulting opportunities are unlimited."

Rafael Dulon has also been working in the hemp industry for some 25 years. In 2015, he was awarded the Global Hemp Innovation Award at the World Hemp Congress for the development of a hemp harvester. Dulon's expertise can be seen in the cultivation, harvesting and further processing of industrial hemp in organic quality. Rafael Dulon, Managing Director of Hanf Farm GmbH and expert member of the International Institute for Cannabinoids (ICANNA) commented on the merger: "The synergies created for Hanf Farm through its inclusion in the SynBiotic SE Group will lead to significantly faster growth. Within SynBiotic SE's strong network of people and companies, we will be much better able to implement our ambitious goals in expanding our capacities and competencies as an original agricultural producer and primary processor of hemp. I am very pleased that Lars Müller fully supports my ideas for the development of sustainable, organic agriculture. Together, we will use the great potential of hemp in agriculture and market our healthy, climate-friendly products even more vigorously, and as well develop many new products. I look forward to using my many years of experience to help support Lars Müller's vision."

An overview of the companies in Daniel Kruse's group:

- Hanf Farm GmbH: The largest organic hemp farm in Europe

- Hempro International GmbH: The largest hemp food distribution in Central Europe, with an international supplier and customer network and profitable own brands

- Hemp Factory GmbH: The largest hemp food production in Central Europe

- MH medical hemp GmbH: CBD expert and wholesaler with THC BtM approval
 

About SynBiotic SE
SynBiotic SE is the largest listed group in Europe in the hemp and cannabis sector and pursues an EU-focused buy & build investment strategy. The group of companies covers the entire supply chain from cultivation to production to retail - from field to shelf. One of the company's core businesses is the research & development, production and marketing of cannabinoid- and terpene-based solutions to major societal problems such as pain, sleep and anxiety. In doing so, SynBiotic SE is active not only in the dietary supplement and cosmetics markets, but also in the medical and, in the future, recreational cannabis sector.



01.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: SynBiotic SE
Barer Str. 7
80333 München
Germany
E-mail: office@synbiotic.com
Internet: https://www.synbiotic.com/
ISIN: DE000A3E5A59
WKN: A3E5A5
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange
EQS News ID: 1253421

 
End of News DGAP News Service

1253421  01.12.2021 

fncls.ssp?fn=show_t_gif&application_id=1253421&application_name=news&site_id=boersengefluester_html
Visual performance / price development - SynBiotic SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.